CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a drug discovery and development company focused on therapeutics targeting Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the 10th Annual Massachusetts Biotechnology Investors Forum on Tuesday, December 9 at 4:20 p.m. (ET) at the Sheraton Hotel in Boston.
